JMJD3 Regulates Abdominal Aortic Aneurysm Expansion
JMJD3 调节腹主动脉瘤扩张
基本信息
- 批准号:10231799
- 负责人:
- 金额:$ 58.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Abdominal Aortic AneurysmAneurysmAnimal ModelAnti-Inflammatory AgentsAortic AneurysmAortic RuptureBlood VesselsCell modelCellsCessation of lifeChromatinChronicClinicalDataDevelopmentDiseaseEnzymesEpigenetic ProcessExhibitsFailureGene ExpressionGenesGeneticGenetic TranscriptionGoalsGrowthHomeostasisHumanImmuneInfiltrationInflammationInflammation MediatorsInflammatoryInterferon-betaInterferonsJanus kinaseKineticsKnowledgeLaboratoriesLeadLeftLifeMediatingMedicalMethodsModelingModificationMolecularMusMyelogenousOperative Surgical ProceduresPathologicPathologyPharmacologyPhenotypePlayPreventionPreventiveProductionProteinsRegulationResolutionRoleRuptureRuptured Abdominal Aortic AneurysmSTAT proteinSecondary toSignal PathwaySmall Interfering RNASpecimenTestingTherapeuticTherapeutic AgentsTissuesTranslatingTreatment EfficacyVascular DiseasesVascular remodelingWorkepigenetic regulationexperimental studyhistone demethylasehistone modificationhuman RNA sequencingimprovedinhibitor/antagonistinnovationinsightkinase inhibitormacrophagemonocytemortalitymouse modelnovelnovel therapeuticsperipheral bloodpre-clinicalpreventpromoterrepairedsingle-cell RNA sequencingtargeted treatmenttranslational approach
项目摘要
PROJECT SUMMARY/ABSTRACT
Abdominal aortic aneurysms (AAA) are a potentially lethal vascular disease that if left untreated, can progress
to aortic rupture which has a mortality rate over 80%. Equally alarming, there are currently no medical
therapies available to limit AAA growth, due in large part to a lack of understanding of the molecular
mechanisms underlying AAA development. Thus, a critical need exists to understand the mechanisms that
govern AAA expansion. One key hallmark of AAAs is inflammatory macrophage (Mφ) infiltration into the
vascular wall. We present data using human single cell RNA sequencing and murine AAA models, that the
histone demethylase, JMJD3, is increased in aortic aneurysm tissue Mφs resulting in a persistent inflammatory
Mφ phenotype with increased production of NFκB inflammatory mediators. Further, using human cells and our
experimental murine model of AAAs, we have identified that interferon-beta (IFNβ), via a janus kinase (JAK) /
signal transducer and activator of transcription (STAT) mechanism induces JMJD3 in Mφs. These results have
led to our hypothesis that IFN?/JAK/STAT signaling directly increases Jmjd3 expression in aortic tissue Mφs
and JMDJ3-mediated epigenetic modifications drive NFkB-mediated inflammatory genes that maintain an
aortic Mφ inflammatory phenotype, thereby promoting AAA development. We further postulate that Mφ
function may be restored via monocyte-Mφ-targeted inhibition of the JMJD3-mediated epigenetic modifications
resulting in the resolution of inflammation and AAA stabilization. This hypothesis will be investigated via the
following specific aims: Aim 1: Elucidate the regulation of NFκB-mediated inflammatory gene expression by
JMJD3 in human and murine AAA monocyte/Mφs. Aim 2: Determine the IFN?/JAK/STAT-mediated
mechanism(s) that regulate Mφ-specific Jmjd3 expression in human and murine AAAs. Aim 3: Examine the
therapeutic efficacy of Mφ-targeted JMJD3 inhibition on AAA expansion. In this translational approach, our
data will pave the way for the development of promising preventive therapeutic agents aimed at cell-specific
targeting of epigenetic enzymes that mediate Mφ inflammation and thereby prevent AAA expansion and
rupture.
项目总结/摘要
腹主动脉瘤(AAA)是一种潜在的致命性血管疾病,如果不及时治疗,可能会进展
主动脉破裂死亡率超过80%同样令人震惊的是,目前没有医疗
限制AAA生长的治疗方法,很大程度上是由于缺乏对AAA分子机制的了解。
AAA发展的基础机制。因此,迫切需要了解
管理AAA扩展。AAAs的一个关键标志是炎性巨噬细胞(Mφ)浸润到
血管壁我们使用人类单细胞RNA测序和小鼠AAA模型提供数据,
组蛋白去甲基化酶JMJD 3在主动脉瘤组织Mφ中增加,导致持续性炎性反应。
Mφ表型与NFκB炎症介质的产生增加。此外,使用人类细胞和我们的
在AAAs的实验小鼠模型中,我们已经确定干扰素β(IFNβ)通过Janus激酶(JAK)/
信号转导子和转录激活子(STAT)机制在Mφ中诱导JMJD 3。这些结果
导致我们的假设,干扰素?/ JAK/STAT信号直接增加主动脉组织Mφ中Jmjd 3的表达
JMDJ 3介导的表观遗传修饰驱动NF κ B介导的炎症基因,
主动脉Mφ炎性表型,从而促进AAA的发展。我们进一步假设Mφ
通过单核细胞-M φ靶向抑制JMJD 3介导的表观遗传修饰,
导致炎症消退和AAA稳定。这一假设将通过
目的1:阐明NFκ B介导的炎症基因表达的调控,
人和鼠AAA单核细胞/Mφ中的JMJD 3。目的2:测定IFN?/ JAK/STAT介导
调节人和鼠AAA中Mφ特异性Jmjd 3表达的机制。目标3:检查
Mφ靶向的JMJD 3抑制对AAA扩张的治疗功效。在这种翻译方法中,我们
这些数据将为开发针对细胞特异性的有前途的预防性治疗剂铺平道路。
靶向介导Mφ炎症的表观遗传酶,从而防止AAA扩张,
破裂
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katherine Ann Gallagher其他文献
Macrophage-Specific Genetic Depletion of Cyclooxygenase-2 Improves Diabetic Wound Healing
- DOI:
10.1016/j.jamcollsurg.2020.07.704 - 发表时间:
2020-10-01 - 期刊:
- 影响因子:
- 作者:
William J. Melvin;Frank Davis;Chris Audu;Emily Barrett;Aaron DenDekker;Sonya Wolf;Amrita Joshi;Katherine Ann Gallagher - 通讯作者:
Katherine Ann Gallagher
Katherine Ann Gallagher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katherine Ann Gallagher', 18)}}的其他基金
The epigenetic regulation of inflammation in tissue repair and vascular disease
组织修复和血管疾病中炎症的表观遗传调控
- 批准号:
10582010 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Nanomedicine-Based Targeting of Inflammatory Macrophages in Diabetic Wound Repair
基于纳米药物的炎症巨噬细胞靶向治疗糖尿病伤口修复
- 批准号:
10467856 - 财政年份:2022
- 资助金额:
$ 58.59万 - 项目类别:
Nanomedicine-Based Targeting of Inflammatory Macrophages in Diabetic Wound Repair
基于纳米药物的炎症巨噬细胞靶向治疗糖尿病伤口修复
- 批准号:
10631233 - 财政年份:2022
- 资助金额:
$ 58.59万 - 项目类别:
Translational research training in cardiovascular science
心血管科学转化研究培训
- 批准号:
10554828 - 财政年份:2022
- 资助金额:
$ 58.59万 - 项目类别:
Targeting jmjd3 mitigates heterotopic ossification
靶向 jmjd3 可减轻异位骨化
- 批准号:
10441559 - 财政年份:2021
- 资助金额:
$ 58.59万 - 项目类别:
JMJD3 Regulates Abdominal Aortic Aneurysm Expansion
JMJD3 调节腹主动脉瘤扩张
- 批准号:
10374155 - 财政年份:2021
- 资助金额:
$ 58.59万 - 项目类别:
Targeting jmjd3 mitigates heterotopic ossification
靶向 jmjd3 可减轻异位骨化
- 批准号:
10315680 - 财政年份:2021
- 资助金额:
$ 58.59万 - 项目类别:
相似海外基金
Establishment of human abdominal aortic aneurysm wall strength prediction model using Ex Vivo Superparamagnetic Iron Oxide–Enhanced Magnetic Resonance Imaging
利用Ex Vivo超顺磁性氧化铁建立人体腹主动脉瘤壁强度预测模型
- 批准号:
23K08226 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
- 批准号:
10595404 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Vascular Smooth Muscle Protein Quality Control and Aortic Aneurysm Formation
血管平滑肌蛋白质量控制与主动脉瘤形成
- 批准号:
10714562 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
- 批准号:
10716621 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Role of mechanical heterogeneity in cerebral aneurysm growth and rupture
机械异质性在脑动脉瘤生长和破裂中的作用
- 批准号:
10585539 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Study on development of prophylaxis for recanalization after coil embolization of cerebral aneurysm and elucidation of its mechanisms
脑动脉瘤弹簧圈栓塞术后再通预防措施的研究进展及机制阐明
- 批准号:
23K08512 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Roles of aging and cellular senescence in the development of intracranial aneurysm rupture
衰老和细胞衰老在颅内动脉瘤破裂发展中的作用
- 批准号:
10680060 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Role of Selective Autophagy of Focal Adhesion in Intracranial Aneurysm
局部粘连选择性自噬在颅内动脉瘤中的作用
- 批准号:
10586692 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Vascular smooth muscle cell ferroptosis and abdominal aortic aneurysm
血管平滑肌细胞铁死亡与腹主动脉瘤
- 批准号:
10733477 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别:
Extracellular Vesicle Delivery System for Treatment of Abdominal Aortic Aneurysm
细胞外囊泡递送系统治疗腹主动脉瘤
- 批准号:
10751123 - 财政年份:2023
- 资助金额:
$ 58.59万 - 项目类别: